Journal of Medical Economics最新文献

{"title":"Beyond direct medical costs: what we miss when indirect costs are ignored.","authors":"Urszula Religioni, Rocío Barrios-Rodríguez, Pilar Requena, Teresa Pakulska","doi":"10.1080/13696998.2026.2670957","DOIUrl":"https://doi.org/10.1080/13696998.2026.2670957","url":null,"abstract":"","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"1487-1491"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147948742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2025 in review: high-impact articles from the <i>Journal of Medical Economics</i>.","authors":"Ivo Abraham, Mike Gregg","doi":"10.1080/13696998.2026.2665047","DOIUrl":"https://doi.org/10.1080/13696998.2026.2665047","url":null,"abstract":"","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"1423-1430"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to \"methodological opacity in sword health digital pelvic health\".","authors":"Fabíola Costa, Ana P Pereira, Andrea M Seet, Beatriz Domingues, Dora Janela, Akshat Pradhan, Anabela C Areias, Xin Tong, Virgílio Bento, Vijay Yanamadala, Steven P Cohen, Jennesa Atherton, Fernando Dias Correia, Luke Belz","doi":"10.1080/13696998.2026.2673766","DOIUrl":"https://doi.org/10.1080/13696998.2026.2673766","url":null,"abstract":"","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"1524-1525"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148138343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness and budget impact of ezetimibe-atorvastatin single-pill combination versus free combination in Chinese adults with hypercholesterolemia.","authors":"Qian Xing, Wendi Cheng, Wei Wang, Weiwei Ren, Yinghuang Wang, Haiyin Wang","doi":"10.1080/13696998.2026.2682693","DOIUrl":"10.1080/13696998.2026.2682693","url":null,"abstract":"<p><strong>Background: </strong>Hypercholesterolemia imposes a growing cardiovascular burden in China, yet low-density lipoprotein cholesterol (LDL-C) target attainment remains low. The single-pill combination (SPC) of ezetimibe and atorvastatin (E/A SPC) was approved in China in 2023 and added to the National Reimbursement Drug List (NRDL) in 2024. Compared with free combination therapy (E/A FCT), E/A SPC may improve adherence and LDL-C reduction, but its economic value has not been assessed in the Chinese context.</p><p><strong>Objective: </strong>To evaluate the cost-effectiveness of E/A SPC versus E/A FCT in Chinese adults with hypercholesterolemia inadequately controlled on statin monotherapy, and to estimate the 5-year budget impact of E/A SPC adoption.</p><p><strong>Methods: </strong>An 11-state Markov model was developed from the Chinese healthcare system perspective, projecting 20-year costs and health outcomes in patients aged 69 years with uncontrolled LDL-C (>70 mg/dL) after statin therapy. Clinical efficacy inputs were derived from a large real-world German head-to-head study (<i>n</i> = 311,242). Subgroup analyses were conducted by age, sex, and cardiovascular risk. A 5-year budget impact analysis estimated the financial consequences of increasing E/A SPC uptake. Costs and outcomes were discounted at 5% annually.</p><p><strong>Results: </strong>E/A SPC generated 0.06 additional quality-adjusted life years (QALYs) at an incremental cost of USD 250.12, yielding an incremental cost effectiveness ratio (ICER) of USD 4,070/QALY, well below the willingness-to-pay threshold of USD 14,423. The probability of cost-effectiveness was 91%. Subgroup analyses consistently favored E/A SPC, with the most favorable ICERs observed in very high-risk patients and middle-aged patients. Over 5 years, E/A SPC was associated with incremental drug spending of USD 372.5 million, partly offset by USD 292.0 million in avoided cardiovascular event costs.</p><p><strong>Conclusion: </strong>E/A SPC is a cost-effective strategy for Chinese adults with hypercholesterolemia inadequately controlled on statin monotherapy, supporting its NRDL inclusion. The study findings should be further validated using larger-scale real-world data from China.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"1677-1687"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148204987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Budget impact of implementing AI-enabled chest X-ray based incidental pulmonary nodule detection for early lung cancer diagnosis: models from Colombia, Costa Rica, Mexico, Thailand and Vietnam.","authors":"Albertus Constantijn Sloof, Sofia Sheveleva, Saniya Pawar, Bhargava Reddy, Bruna Dirodi, Bibiana Paola Garcia Peña, Rosario Mata Coto, Sebastián Cortés, Danai Chinnacom, Hoai Thanh Van Pham","doi":"10.1080/13696998.2026.2682681","DOIUrl":"10.1080/13696998.2026.2682681","url":null,"abstract":"<p><strong>Objective: </strong>To assess the budget impact of incidental pulmonary nodule (IPN) detection using an artificial intelligence-software for chest X-ray (CXR) interpretation - qXR - for early lung cancer (LC) detection in Vietnam, Colombia, Thailand, Costa Rica, and Mexico.</p><p><strong>Methods: </strong>Country-specific hybrid decision-tree and budget impact models were developed from the public payer perspective over a 5-year time horizon. Each compared current symptomatic LC detection with a scenario adding AI-enabled Chest X-Ray for IPN detection and referral to low-dose computed tomography. Costs included diagnostics, set-up, treatment, healthcare resource use, and end-of-life care, expressed in 2024 USD. One-way sensitivity and scenario analyses tested parameter and structural uncertainty.</p><p><strong>Results: </strong>Over the 5-year time horizon, the implementation of AI-enabled CXR for IPN detection is estimated to avert 24,763 premature deaths across the five countries, improving survival and lowering long-term expenditures. Following the introduction of qXR, more costs were incurred due to additional patients being diagnosed and treated. This resulted in fewer late-stage patients and cost savings. The breakeven point was reached in year 3 for Vietnam, Thailand, Colombia, and Mexico and in year 4 for Costa Rica. Cost savings were primarily driven by the stage shift towards earlier detection, where treatment costs are lower and survival outcomes are better.</p><p><strong>Conclusions: </strong>Integrating AI-enabled CXR for IPN detection into national hospital workflows may enable earlier LC detection and achieve cost neutrality within 5 years in low- and middle-income countries. These findings support the economic feasibility and scalability of AI-assisted imaging as part of national lung cancer control strategies.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"1779-1799"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148308295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Model-based evaluation of colorectal cancer screening effectiveness: three rounds of multitarget stool DNA testing versus one colonoscopy.","authors":"Michael Dore, Derek W Ebner, Vahab Vahdat, Chris Estes, A Burak Ozbay, Victoria Foster, Paul J Limburg","doi":"10.1080/13696998.2026.2645491","DOIUrl":"10.1080/13696998.2026.2645491","url":null,"abstract":"<p><strong>Background: </strong>Several colorectal cancer (CRC) screening modalities are guideline-recommended in the United States but differ in screening interval and real-world adherence. Accordingly, single-round test performance may not reflect cumulative effectiveness over time. This study compared the 10-year longitudinal outcomes of two CRC screening strategies-triennial next-generation multitarget stool DNA testing (ng mt-sDNA) and decennial screening colonoscopy.</p><p><strong>Methods: </strong>The validated, microsimulation-based Colorectal Cancer and Adenoma Incidence and Mortality (CRC-AIM) model was used to estimate 10-year cumulative outcomes for two guideline-recommended screening strategies: triennial ng mt-sDNA and decennial colonoscopy. Model inputs included test performance and real-world adherence. Outcomes included CRC and precancerous lesions detected, CRC mortality reductions, and life-years gained (LYG). Sensitivity analyses examined the effects of varying screening adherence and follow-up colonoscopy adherence.</p><p><strong>Results: </strong>Over 10 years per 1,000 individuals offered screening, ng mt-sDNA detected 13% more precancerous lesions and 11% more CRC cases than colonoscopy, with a greater proportion of CRCs identified through screening rather than symptomatic detection. ng mt-sDNA achieved greater CRC mortality reduction (33% vs 20%) and 62% more life-years gained, with consistent findings across sensitivity analyses.</p><p><strong>Conclusions: </strong>With real-world adherence, screening with triennial ng mt-sDNA demonstrates superior cumulative effectiveness compared with decennial colonoscopy, driven by higher adherence and favorable longitudinal performance. These findings support expanded use of noninvasive stool-based screening to reduce CRC mortality and alleviate colonoscopy capacity constraints. Broader adoption of ng mt-sDNA may enhance population-level CRC prevention by increasing participation and improving early detection.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"986-993"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147512610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness, public health impact, and budget impact of receipt of Pfizer-BioNTech COVID-19 vaccine, LP.8.1-adapted, 2025/2026 formula among adults aged 18 years and older at high risk for severe outcomes from COVID-19 in the United States.","authors":"Alon Yehoshua, Manuela Di Fusco, Abby E Rudolph, Elizabeth Thoburn, Santiago M C Lopez, Josie Dodd, Benjamin Yarnoff","doi":"10.1080/13696998.2026.2644761","DOIUrl":"10.1080/13696998.2026.2644761","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the cost-effectiveness, public health impact, and budget impact of receiving the LP.8.1-adapted Pfizer-BioNTech COVID-19 Vaccine among United States adults aged ≥ 18 years.</p><p><strong>Methods: </strong>A previously published economic model was adapted to compare receiving the LP.8.1-adapted Pfizer-BioNTech COVID-19 Vaccine (2025/2026 formula) versus not in adults aged 18-64 years at high risk of severe COVID-19 and all adults aged ≥ 65 years. Age-specific epidemiological inputs were derived from public health surveillance data. Clinical, cost, and vaccine effectiveness parameters were informed by published literature. The budget impact analysis was based on a hypothetical 1-million-member plan and used a payer perspective.</p><p><strong>Results: </strong>Without vaccination, the model projected 41.5 million new symptomatic cases, 43,681 deaths, 338,252 hospitalizations, $80 billion in total costs, and 1.99 million QALYs lost among adults aged ≥18 years, with the greatest health burden observed among adults aged ≥65 years (73% of hospitalizations and 83% of deaths) and the greatest economic burden in adults aged 18 to 64 years at high risk of severe outcomes (62% of total costs). Compared to no vaccination, vaccination with the LP.8.1-adapted Pfizer-BioNTech COVID-19 vaccine (2025/2026 formula) in the populations aged 18 to 64 years and ≥18 years, respectively was projected to prevent 212,096 and 620,333 cases, 137 and 1,867 deaths, and 1,501 and 12,677 hospitalizations, resulting in incremental costs of $1.1 billion and $567 million, 2,411 and 15,430 LYs gained, 70,493 and 181,137 QALYs gained, ICERs of $16,238 and $3,137 from the societal perspective and $34,022 and $8,059 from the payer perspective. In the budget impact analysis from the payer perspective, vaccination was estimated to result in a modest budget increase.</p><p><strong>Conclusions: </strong>Vaccinating adults at high risk of severe COVID-19 with the LP.8.1-adapted Pfizer BioNTech COVID-19 Vaccine is projected to be a cost-saving measure from the societal perspective that could reduce the public health and economic burden of COVID-19.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"1027-1045"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147529749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical burden and healthcare resource utilization after allogeneic hematopoietic stem cell transplant for sickle cell disease or β-thalassemia.","authors":"Duncan Brown, Nanxin Li, Jiahe Li, Suzan Imren, Kristin A Evans, Michelle Jerry","doi":"10.1080/13696998.2026.2660597","DOIUrl":"10.1080/13696998.2026.2660597","url":null,"abstract":"<p><strong>Introduction: </strong>Allogeneic hematopoietic stem cell transplant (allo-HSCT) is a potentially curative treatment for patients with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or β-thalassemia. Real-world data on post-allo HSCT outcomes are limited among these patients.</p><p><strong>Methods: </strong>Patients with SCD with recurrent VOCs or β-thalassemia with allo-HSCT were identified in the Merative MarketScan Research Databases. Clinical outcomes, allo-HSCT complications, and healthcare resource utilization were summarized after allo-HSCT.</p><p><strong>Results: </strong>Eighty-one patients with SCD with recurrent VOCs and 33 with β-thalassemia were included. About one-third of patients with SCD experienced a VOC and one-quarter of patients with β-thalassemia required a red blood cell transfusion, in the year after the first 100 days following allo-HSCT. Approximately 40.7% of patients with SCD and 42.4% of patients with β-thalassemia developed acute graft-versus-host disease (GvHD), while 32.1% and 27.3% developed chronic GvHD, respectively. Patients with SCD had a mean of 74.1 (59.6) outpatient visits per patient per year and patients with β-thalassemia had a mean (SD) of 76.1 (61.3).</p><p><strong>Limitations: </strong>Due to the lack of International Classification of Diseases, 10th Revision (ICD-10) codes to distinguish between different types of allo-HSCT, this study was unable to assess outcomes of patients with haploidentical hematopoietic stem cell transplantation (haplo-HSCT), which is a type of allo-HSCT.</p><p><strong>Conclusion: </strong>Many patients with SCD with recurrent VOCs or β-thalassemia endure potentially life-threatening transplant-related complications and require substantial healthcare utilization following allo-HSCT. These findings suggest limitations of allo-HSCT and underscore the need for alternative curative treatment options.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"1405-1419"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147773869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Budget impact analysis of delgocitinib for moderate to severe Chronic Hand Eczema in the United States.","authors":"Jianni Singh-Landa, Aseel Bin Sawad, Yasmin Bappoo, Ben Llewellyn, Megan Barnes, Douglas Maslin, Sanjeev Balu","doi":"10.1080/13696998.2026.2675851","DOIUrl":"10.1080/13696998.2026.2675851","url":null,"abstract":"<p><strong>Background: </strong>Chronic Hand Eczema (CHE) is an inflammatory skin disease defined as eczema affecting the hands and/or wrists lasting >3 months and/or re-occurring ≥2 times per year. Delgocitinib cream 20 mg/g, a topical janus kinase inhibitor (JAKi), is approved in multiple countries for the treatment of moderate to severe CHE in adults who have had an inadequate response to topical corticosteroids (TCS) or for whom TCS are inadvisable. This budget impact analysis aimed to estimate the economic impact of the introduction of delgocitinib cream as a treatment for moderate to severe CHE in the United States (US).</p><p><strong>Methodology: </strong>The model was developed with a 3-year time horizon from the perspective of a hypothetical US commercial healthcare plan involving one million members. Comparator treatments included other topical and oral JAKis and biologics. Proportions of patients using each treatment were accounted for in calculating healthcare costs. The eligible population with moderate to severe CHE refractory to steroids was estimated considering prevalent and incident populations. Different healthcare costs, including drug, monitoring, and adverse event (AE) costs, were accounted for. AEs were included based on clinical trial data. Costs were adjusted to 2024.</p><p><strong>Results: </strong>Of one million members overall, the study population included 10,494, 11,095, and 11,696 patients with CHE in Years 1, 2 and 3, respectively. The introduction of delgocitinib cream was associated with overall cost savings of $2,973,478 in Year 1, $21,424,214 in Year 2, and $63,355,366 in Year 3, constituting total accumulated savings of $87,753,057. Savings were derived almost entirely from drug costs (97.2%), with reduced AE (1.54%) and monitoring costs (1.27%) also contributing.</p><p><strong>Conclusion: </strong>Adoption of delgocitinib cream for moderate to severe CHE in adults for whom TCS were inadequate or inadvisable is predicted to generate significant cost savings to US commercial healthcare plans over 3 years.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"1555-1564"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148042596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness analysis of capivasertib plus fulvestrant in the <i>PIK3CA/AKT1/PTEN</i>-altered subgroup with HR+/HER2- advanced breast cancer: a United States payer perspective.","authors":"Xi Liang, Daniel C Malone, Chia Jie Tan","doi":"10.1080/13696998.2026.2656072","DOIUrl":"10.1080/13696998.2026.2656072","url":null,"abstract":"<p><strong>Aims: </strong>Capivasertib plus fulvestrant has emerged as a promising targeted therapy for HR+/HER2- advanced breast cancer (ABC). This study evaluated the cost-effectiveness of capivasertib plus fulvestrant vs. fulvestrant monotherapy in <i>PI3K/AKT/PTEN</i> pathway-altered patients with HR+/HER2- ABC from a U.S. payer's perspective.</p><p><strong>Materials and methods: </strong>A partitioned survival model with three health states (progression-free, progressive disease, and death) was developed over a 5-year time horizon. Progression-free survival (PFS) and overall survival (OS) data were derived from the CAPItello-291 trial (NCT04305496). Utility, disutility, and direct medical costs were obtained from published literature and the Centers for Medicare and Medicaid Services. Capivasertib cost was based on wholesale acquisition cost. Costs were presented in 2025 U.S. dollars. Both costs and outcomes were discounted by 3%. Incremental cost-effectiveness ratios (ICERs) based on quality-adjusted life-year (QALY) gained and equal value of life years gained (evLYG) were compared using a willingness-to-pay (WTP) threshold of $150,000. Sensitivity analyses, scenario analyses (10-year horizon and phase II trial data) and threshold analysis were conducted.</p><p><strong>Results: </strong>Capivasertib plus fulvestrant yielded more QALYs (1.89 vs. 1.29) and life years (3.31 vs. 2.49) but higher costs ($539,625 vs. $158,679) than fulvestrant alone, resulting in ICERs of $636,455/QALY gained and $459,358/evLYG over a 5-year time horizon. The cost of capivasertib ($28,332/4 weeks) had the greatest impact and would need to be reduced to $5,598/4 weeks to achieve cost-effectiveness.</p><p><strong>Limitations: </strong>Extrapolation of survival data reflects limited long-term trial data and increases uncertainty surrounding model parameters. Efficacy based on clinical trials may differ from real-world effectiveness.</p><p><strong>Conclusions: </strong>Despite clinical benefits, capivasertib plus fulvestrant was not cost effective at current price from a U.S. payer's perspective. The cost of capivasertib per 4 weeks would be required to decrease by ∼80% from $28,332 to $5,598 (about $87 per 200 mg) to meet the WTP threshold of $150,000.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"1213-1229"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147729332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}